CONSOLIDATED STATEMENT OF EQUITY - USD ($) $ in Thousands	Total	Acquisitions And Asset Purchases	DeepHealth, Inc.	Parent	Parent Acquisitions And Asset Purchases	Parent DeepHealth, Inc.	Common Stock	Common Stock Acquisitions And Asset Purchases	Common Stock DeepHealth, Inc.	Additional Paid-in Capital	Additional Paid-in Capital Acquisitions And Asset Purchases	Additional Paid-in Capital DeepHealth, Inc.	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2018							48,977,485
Beginning balance, value at Dec. 31, 2018	$ 200,253			$ 127,184			$ 5			$ 242,835			$ 2,259	$ (117,915)	$ 73,069
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock upon exercise of options (in shares)							12,500
Issuance of stock upon exercise of options	75			75						75
Stock-based compensation (in shares)							771,042
Stock-based compensation	8,735			8,735						8,735
Forfeiture of restricted stock (in shares)							(1,500)
Forfeiture of restricted stock	$ (5)			(5)						(5)
Non-cash severance (in shares)	12,692
Non-cash severance	$ 188
Issuance of stock for acquisitions (in shares)							542,109
Issuance of stock for acquisitions	7,500			7,500						7,500
Sale to noncontrolling interests, net of taxes	5,545			3,537						3,537					2,008
Contributions from noncontrolling interests	750														750
Distributions paid to noncontrolling interests	(3,057)														(3,057)
Change in cumulative foreign currency translation adjustment	(32)			(32)									(32)
Change in fair value cash flow hedge, net of taxes	(10,253)			(10,253)									(10,253)
Change in fair value of cash flow hedge from prior periods reclassified to earnings	0
Net income (loss)	23,440			14,756										14,756	8,684
Ending balance, value at Dec. 31, 2019	233,139			151,685			$ 5			262,865			(8,026)	(103,159)	81,454
Ending balance (in shares) at Dec. 31, 2019							50,314,328
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	12,463			12,463						12,463
Shares issued under the equity compensation plan (in shares)							491,674		10,920
Issuance of common stock for sale of unregistered securities for the DeepHealth acquisition (in shares)							823,615
Issuance of common stock for sale of unregistered securities for the DeepHealth acquisition	33,011			33,011						33,011
Tax effect on gain on sale of noncontrolling interest	(551)			(551)						(551)
Distributions paid to noncontrolling interests	(1,985)														(1,985)
Change in cumulative foreign currency translation adjustment	(101)			(101)									(101)
Change in fair value cash flow hedge, net of taxes	(19,372)			(19,372)									(19,372)
Change in fair value of cash flow hedge from prior periods reclassified to earnings	3,448			3,448									3,448
Net income (loss)	(1,749)			(14,840)										(14,840)	13,091
Ending balance, value at Dec. 31, 2020	258,303			165,743			$ 5			307,788			(24,051)	(117,999)	92,560
Ending balance (in shares) at Dec. 31, 2020							51,640,537
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock upon exercise of options (in shares)							53,960
Issuance of stock upon exercise of options	488			488						488
Stock-based compensation	25,284			25,284						25,284
Shares issued under the equity compensation plan (in shares)							1,212,758		471,162
Forfeiture of restricted stock (in shares)							(4,365)
Forfeiture of restricted stock	(81)			(81)						(81)
Gain on contribution of assets to majority owned subsidiary	(4)			(4)						(4)
Contribution from noncontrolling partner	123														123
Issuance of stock for acquisitions (in shares)								82,658	91,517
Issuance of stock for acquisitions		$ 2,498	$ 2,413		$ 2,498	$ 2,413					$ 2,498	$ 2,413
Sale to noncontrolling interests, net of taxes	11,610			4,206						4,206					7,404
Distributions paid to noncontrolling interests	(2,426)														(2,426)
Change in cumulative foreign currency translation adjustment	(65)			(65)									(65)
Change in fair value cash flow hedge, net of taxes	0
Change in fair value of cash flow hedge from prior periods reclassified to earnings	3,695			3,695									3,695
Net income (loss)	44,319			24,727										24,727	19,592
Ending balance, value at Dec. 31, 2021	$ 346,157			$ 228,904			$ 5			$ 342,592			$ (20,421)	$ (93,272)	$ 117,253
Ending balance (in shares) at Dec. 31, 2021							53,548,227